EYE Stock Overview
Designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Nova Eye Medical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.14 |
| 52 Week High | AU$0.33 |
| 52 Week Low | AU$0.13 |
| Beta | 0.92 |
| 1 Month Change | -6.45% |
| 3 Month Change | -14.71% |
| 1 Year Change | 20.83% |
| 3 Year Change | -53.23% |
| 5 Year Change | -80.27% |
| Change since IPO | -75.54% |
Recent News & Updates
We Think Nova Eye Medical (ASX:EYE) Can Afford To Drive Business Growth
Nov 04
Nova Eye Medical Limited (ASX:EYE) Might Not Be As Mispriced As It Looks After Plunging 26%
Sep 22Recent updates
We Think Nova Eye Medical (ASX:EYE) Can Afford To Drive Business Growth
Nov 04Nova Eye Medical Limited (ASX:EYE) Might Not Be As Mispriced As It Looks After Plunging 26%
Sep 22Take Care Before Diving Into The Deep End On Nova Eye Medical Limited (ASX:EYE)
Aug 06Nova Eye Medical Limited (ASX:EYE) Soars 29% But It's A Story Of Risk Vs Reward
Apr 18Is There An Opportunity With Nova Eye Medical Limited's (ASX:EYE) 43% Undervaluation?
Mar 26News Flash: Analysts Just Made A Captivating Upgrade To Their Nova Eye Medical Limited (ASX:EYE) Forecasts
Jan 19Further Upside For Nova Eye Medical Limited (ASX:EYE) Shares Could Introduce Price Risks After 38% Bounce
Dec 27We're Not Very Worried About Nova Eye Medical's (ASX:EYE) Cash Burn Rate
Sep 03Improved Revenues Required Before Nova Eye Medical Limited (ASX:EYE) Stock's 43% Jump Looks Justified
Apr 17Is Nova Eye Medical (ASX:EYE) In A Good Position To Invest In Growth?
Dec 16We Think Nova Eye Medical (ASX:EYE) Needs To Drive Business Growth Carefully
Aug 27Shareholder Returns
| EYE | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | 3.6% | -1.1% | -2.7% |
| 1Y | 20.8% | 0.4% | 6.5% |
Return vs Industry: EYE exceeded the Australian Medical Equipment industry which returned 0.4% over the past year.
Return vs Market: EYE exceeded the Australian Market which returned 6.5% over the past year.
Price Volatility
| EYE volatility | |
|---|---|
| EYE Average Weekly Movement | 8.1% |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in AU Market | 16.8% |
| 10% least volatile stocks in AU Market | 3.1% |
Stable Share Price: EYE has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: EYE's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1970 | n/a | Tom Spurling | www.nova-eye.com |
Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. The company offers iTrack, a glaucoma surgical device to reduce intraocular pressure in adult patients with open-angle glaucoma; iTrack Advance, a canaloplasty microcatheter which offers malleability and manoeuvrability than common nylon alternatives; Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma; and 2RT, a proprietary laser technology to treat patients in early/intermediate age-related macular degeneration. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020.
Nova Eye Medical Limited Fundamentals Summary
| EYE fundamental statistics | |
|---|---|
| Market cap | AU$33.21m |
| Earnings (TTM) | -AU$8.79m |
| Revenue (TTM) | AU$23.33m |
1.4x
P/S Ratio-3.8x
P/E RatioIs EYE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EYE income statement (TTM) | |
|---|---|
| Revenue | AU$23.33m |
| Cost of Revenue | AU$3.13m |
| Gross Profit | AU$20.19m |
| Other Expenses | AU$28.98m |
| Earnings | -AU$8.79m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.038 |
| Gross Margin | 86.57% |
| Net Profit Margin | -37.68% |
| Debt/Equity Ratio | 0% |
How did EYE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 01:50 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nova Eye Medical Limited is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tanushree Jain | Bell Potter |
| Anthony Vendetti | Maxim Group |
| Michael Youlden | MST Financial Services Pty Limited |